The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis and uterine fibroids , as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. Your Contributions (include, but are not limited to): Serve as the strategic partner to Program Team Leads and cross-functional stakeholders, including clinical development, commercial, market access, technical operations, regulatory, safety, and medical affairs, to develop, align, and execute integrated program strategy within the therapeutic area and portfolio context.